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B acute lymphoblastic leukemia (B-ALL) cells are distinctively vulnerable to endoplasmic reticulum (ER) stress. Recently,
inhibition of p97was shown to induce ER stress and subsequently cell death in solid tumors and inmultiplemyeloma.We
investigated the role of a novel, orally available, p97 inhibitor (CB-5083; Cleave Biosciences) in B-ALL. CB-5083 induced a
significant reduction in viability in 10 human B-ALL cell lines, harboring the most common fusion-genes involved in
pediatric and adult B-ALL, with IC50s ranging from 0.34 to 0.76 μM. Moreover, CB-5083 significantly reduced the colony
formation of OP1 and NALM6 cells. Early and strong induction of apoptosis was demonstrated in BALL1 and OP1 cells,
togetherwith a robust cleavageofPARP.CB-5083 inducedERstress, asdocumented through: 1) prominent expressionof
chaperones (GRP78, GRP94, PDI, DNAJC3, and DNAJB9); 2) increased activation of IRE1-alpha, as demonstrated by the
splicing of XBP1; and 3) activation of PERK, which resulted in a significant overexpression of CHOP, and its downstream
genes. CB-5083 reduced the viability also in GRP78−/−, GRP94−/−, and XBP1−/− cells, suggesting that none of these
proteins alone was strictly required for CB-5083 activity. Moreover, we showed that the absence of XBP1 (XBP1−/−)
increased the sensitivity to CB-5083, leading to the hypothesis that XBP1 splicing counteracts the activity of CB-5083,
probablymitigatingERstress. Finally, vincristinewas synergisticwithCB-5083 in bothBALL1andOP1cells. In summary,
the targeting of p97 with CB-5083 is a novel promising therapeutic approach that should be further evaluated in B-ALL.
Neoplasia (2017) 19, 750–761bbreviations: B-ALL, B acute lymphoblastic leukemia; ER, endoplasmic reticulum;
PR, unfolded protein response; ERAD, ER-associated degradation; MTT,
-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; HNA, 2-hydroxy-1-
aphthaldehyde; PI, propidium iodide; PEI, polyethylenimine; 4-OHT, 4-hydroxy
moxifen
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Acute Lymphoblastic Leukemia
In the United States each year, approximately 6000 patients are
diagnosed with acute lymphoblastic leukemia (ALL) [1]; half of these
are adults. Survival rate in children and adolescents has increased from
less than 10% in the 1960s to 90% today [1], but these results are not
replicated in adults [2]. Indeed, the long-term overall survival in
adults is only 30% to 40% for those younger than 60 years and less
than 10% for those older than 60 years [3,4]. Therefore, new
treatment options are clearly needed in these patients; and recent
efforts have introduced targeted therapies that focus on specificA
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Neoplasia Vol. 19, No. 10, 2017 Inhibition of p97 in B-ALL Gugliotta et al. 751weaknesses of ALL cells [5]. In this context, B-ALL cells were recently
noted to be distinctively vulnerable to endoplasmic reticulum (ER)
stress, identifying the unfolded protein response (UPR) as a novel
therapeutic target in acute leukemia [6,7].igure 1. Evaluation of viability, proliferation, and clonogenic potential of B-ALL cell lines treatedwith CB-5083. (A) Fusion genes associatedwith
0 human B-ALL cell lines treated with CB-5083, and their corresponding IC50s (mean, and 95% confidence intervals, CIs). For each cell line,
iabilitywasmeasured at 72 hours byMTT assays (3 experiments, each in triplicates). *: t(5;12)(q31q33; p12), which is not associatedwith usual
sion genes in B-ALL. (B) MTT assays of the 10 B-ALL cell lines treated with CB-5083: viability measured at 72 hours expressed as% of control
ehicle – DMSO); mean ± SD of three experiments in triplicates for each cell line. (C) Proliferation assays of three cell lines (BALL1, OP1, and
EH) treated with different concentrations of CB-5083 for various durations. Viable cells were counted at 24, 48, 72, and 96 hours (trypan blue
xclusion). Experiments (n = 3) were done in duplicates; proliferation is expressed as fold changes (mean ± SD) compared to baseline (=1).
) MTT assays of two cell lines (BALL1 and OP1): viability measured at 24 hours expressed as % of control (vehicle – DMSO); mean ± SD of
ree experiments in triplicates for each cell line. (E) Colony assays in methyl-cellulose of the OP1 and NALM6 cells: cells were plated in
ethyl-cellulose in the presence of different concentrations of CB-5083, and the resulting colonies (OP1, at 15 days; NALM-6, at 12 days) were
ounted. Experiments (n = 3) were done in duplicates, and the number of colonies in experimental wells is expressed as% (mean [numbers inF
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the boxes] ± SD) of colonies in the diluent control.ER Stress and Unfolded Protein Response
The ER is an intracellular organelle with fundamental functions in the
secretory pathway, including translocation, folding, and posttranslational
modifications of proteins. The ER stress refers to those conditions that
752 Inhibition of p97 in B-ALL Gugliotta et al. Neoplasia Vol. 19, No. 10, 2017affect ER function. Under ER stress, the cell activates UPR, a complex
system that tries to restore protein homeostasis by increasing expression of
ER chaperones, reducing the protein loading to ER through inhibition of
mRNA translation, and promoting ER-associated degradation (ERAD)
[8]. If these adaptive mechanisms fail, UPR is able to activate pathways
leading to apoptosis [9]. UPR takes place through three different
branches in which the signaling is initially mediated by IRE1-alpha
(inositol-requiring protein-1 alpha), PERK (Protein kinase RNA-like ER
kinase), and ATF6 (activating transcription factor 6). The chaperone
GRP78 (BIP) is the main sensor of ER stress. Under physiological
conditions, it binds IRE1-alpha, PERK, and ATF6, preventing their
activation. However, in the presence of excess of unfolded proteins (higher
levels of ER stress), GRP78 binds to these unfolded proteins and dissociates
from IRE1-alpha, PERK, and ATF6, resulting in their activation.
p97 and ERAD
Valosin-containing protein, p97 (VCP/p97, Cdc48 in yeast) [10] is
an abundant, conserved ATPase involved in diverse cellular
activities, including ERAD, chromatin-associated degradation,
mitochondria-associated degradation, and autophagy [11–13]. ERAD
requires the retrograde (fromER to cytoplasm) transportation of unfolded
proteins, which are ultimately destroyed by the ubiquitin-proteasome
system. The activity of the p97 protein in ERAD is mediated by the
formation of a complex with two co-factors: ubiquitin fusion-degrading
protein 1 (Ufd1) and nuclear protein localization protein 4 homolog
(Npl4). The p97-Ufd1-Npl4 complex is recruited to the ER membrane,
where it plays a fundamental role in the extraction of the protein from the
ER lumen to the cytosol. Loss of p97 ATPase activity blocks proteasomal
degradation of several different ERAD substrates [11].
Pharmacological inhibition of p97 induces ER stress and subsequently
cell death in solid tumors [14,15] and in multiple myeloma [15], with
promising activity and tolerability in in vivo models. On that basis, two
phase I clinical trials with a novel, orally available, p-97 inhibitor CB-5083
(Cleave Biosciences) [15,16] have been initiated in these settings
(ClinicalTrials.gov: NCT02243917 and NCT02223598). However, no
data are available on effects of the inhibition of p97 in B-ALL. For these
reasons, we investigated the role of CB-5083 in B-ALL models.Methods
Detailed methods are described in the supplemental material.
Cell Lines
The following human B-ALL cell lines were used: BALL1, REH,
NALM6, OP1, ALL-PO, 697, RS4;11, BV173, SEM, and SUPB15.
OP1 cells were generously provided by Dario Campana (National
University Cancer Institute, Singapore). ALL-PO cells were gener-
ously provided by Andrea Biondi (University of Milan-Bicocca,
Monza, Italy). Murine BCR-ABL transformed B-ALL cell lines with
floxed alleles (XBP1FL/FL, GRP78FL/FL, or GRP94FL/FL) were used.
Viability Assay and Evaluation for Synergy
Cell viability was evaluated by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. Half maximal inhibitory
concentrations (IC50s) were calculated using the GraphPad Prism 6
software. For pulse exposure assays, cells were treatedwithCB-5083 for the
desired interval, washed three times with phosphate buffer saline (PBS),
and seeded with fresh media, and viability was evaluated by MTT assay.
For drug combination assays, cells were seeded in 96-well
plates, followed by addition of either vehicle or increasingconcentrations of CB-5083 alone, second drug (vincristine, bortezo-
mib, 2-hydroxy-1-naphthaldehyde [HNA], or prednisolone) alone, or
CB-5083 plus second drug. Viability was evaluated by MTT assay as
previously described. Synergistic combination of two drugs was
determined using the CompuSyn software. The extent of drug
interaction between the two drugs was determined using the
combination index (CI) for mutually exclusive drugs. CI values
were obtained when solving the equation for different concentrations
of drugs. A CI of 1 indicates an additive effect, whereas a CI of b1
denotes synergy.
Cell Proliferation and Clonogenic Assay
Cell proliferation was evaluated with trypan blue exclusion. For
clonogenic assay, either NALM-6 or OP1 cells were grown in
methyl-cellulose (Methocult H4230, STEMCELL Technologies).
Colonies were counted under an inverted microscope after either 12
(NALM6) or 15 days (OP1).
Apoptosis and Cell Cycle Analysis
Apoptosis was determined by Annexin V/PI staining (BD
Biosciences) according to manufacturer's instructions. Cell cycle
analyses were performed by propidium iodide staining (Sigma-
Aldrich) for DNA content and flow cytometric analysis. All flow
cytometry data were analyzed using FlowJo software (Tree Star,
Ashland, OR).
Western Blotting and PCR
Western blotting and PCR were performed as previously described
[7], following standard procedures.
Retroviral Transduction and Inducible Knockout
Retroviral constructs and the corresponding empty vector controls
were packaged in Platinum-E (Plat-E) cells using polyethylenimine (PEI)
transfection method. Nine micrograms of plasmid (either MSCV-ERT2
or MSCV-Cre-ERT2) was incubated with 27 μl of PEI reagent (1 μg/μl)
in 1000 μl Opti-MEMmedia (Invitrogen) for 20 minutes. The mixture
was placed on the Plat-E cells in 10-cm culture dishes. The virus
supernatants were harvested 24 and 48 hours later. Viral supernatants
from two collections were combined, filtered through a 0.45-μm filter,
and loaded on RetroNectin (Clontech)-coated nontissue 6-well plates,
and 2 × 106 cells (BCR-ABL+ B-ALL GRP78FL/FL, GRP94FL/FL, or
XBP1FL/FL) per well were transduced following the manufacturer's
instructions. These transduced cells were selected for 48 to 72 hours with
puromycin (1-2 μM). CRE-mediated deletion of GRP78, GRP94, or
XBP1 was accomplished by treatment of these cells with 4-OHT (1 μM)
for 2 days.
Statistical Analysis
IC50s are expressed as mean and 95% confidence intervals. All
other results are expressed as mean ± SD. Statistical significance was
determined by Student’s t test or one-way ANOVA, as appropriate.
Significance of P values less than .05, .01, .001, and .0001 is shown
with *, **, ***, and **** asterisks, respectively.
Results
Viability, Proliferation, and Colony Assay
CB-5083 was tested against a panel of 10 human B-ALL cell lines
harboring the most common fusion genes involved in pediatric and
adult B-ALL [17] (Figure 1A). Viability after 72 hours of treatment
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assays (n = 3). CB-5083 demonstrated robust activity against all the
cell lines, with IC50s ranging from 0.34 μM (BALL1) to 0.76 μM
(BV173) (Figure 1, A and B). Moreover, the IC90s were below 1 μM
in 8/10 tested cell lines (exception was REH and BV173) (Figure 1B).
Further, the proliferation of BALL1, OP1, and REH cells exposed
to different CB-5083 concentrations was evaluated by trypan blue
exclusion at 24, 48, 72, and 96 hours (Figure 1C). At 96 hours,
treatment with CB-5083 (0.5 μM and 0.75 μM) significantly
reduced the number of viable cells compared to untreated cells (fold
changes with respect to baseline are reported in Supplemental Table
1). Of note, treatment of BALL1 and OP1 with CB-5083 0.75 μM
significantly lowered the number of viable cells compared to baseline,
suggesting a cytotoxic activity of CB-5083, which was already
pronounced at 48 hours; in REH cells, at 0.75 μM, the number of
viable cells remained almost unchanged, suggesting a cytostatic
activity. The rapid activity of CB-5083 was confirmed by MTT assays
after a short exposure (24 hours) to the drug, with an IC50s of 0.68 μM
and 0.64 μM for BALL1 and OP1 cells, respectively (Figure 1D).
We then evaluated the clonogenic potential of B-ALL cells under
continuous exposure to the drug (Figure 1E). Colonies of NALM6
and OP1 were grown in methyl-cellulose under different drug
concentrations (0.1, 0.5, and 1 μM). CB-5083 was not effective at
the lowest concentration tested (0.1 μM). In cells treated with higher
concentrations, a significant reduction occurred in the number of
colonies (% decreased compared to control [untreated cells]; mean ±
SD): OP1, 70% (±5.5) and 38% (±2.5) at 0.5 μM and 1 μM,
respectively; NALM6, 81% (±4.6) and 56% (±6.6) at 0.5μMand 1μM,
respectively. Moreover, after treatment with 1 μM, colonies appeared
smaller compared to control (morphologic observation, data not shown).
Apoptosis and Cell Cycle
To confirm the cytotoxic activity of CB-5083, we evaluated the
rates of apoptosis at 24, 48, and 72 hours after treatment with
CB-5083 (0.25, 0.5, and 0.75 μM). Apoptosis was measured by flow
cytometry, after staining with Annexin V and propidium iodide, in
BALL1 (Figure 2) and OP1 (Supplemental Figure 1). CB-5083
induced apoptosis in both cell lines. For BALL1, at 24 hours, the
proportion of apoptotic cells was significantly higher in treated
(0.75 μM: 54%; 0.5 μM: 29%) versus control cells (14%; P b .0001,
and P = .02, respectively); the degree of apoptosis increased at later
time points andwasmassive at 72 hours (0.75μM:94%; 0.5μM:71%;
control: 15%; P b .0001 for both comparisons). A similar trend,
although to a lower degree, was found also for OP1 (Supplemental
Figure 1).
By Western blot (Figure 3, A and B), we showed a significant
cleavage of PARP1 in BALL1 and OP1 cells as early as 8 hours of
treatment; cleaved PARP was documented even at 24 hours in cells
treated with CB-5083 (0.75 μM).
Cell cycle analysis was performed (Figure 4); considering that
marked rates of apoptosis were observed at 24 hours, we investigated
the effects on the cell cycle at an earlier exposure (12 hours) of
CB-5083 but at a higher dose (1 μM). Compared to control, for both
BALL1 and OP1, a significant difference did not occur in the
percentage of cells with N2 N DNA content, suggesting that cells
already in S phase were able to continue to the G2/M phase. On the
contrary, a significantly lower number of cells with 2 N DNA content
(diploid) were noted, associated with a proportional increase of cells
with b2 N DNA content (sub-G1; apoptotic cells). These findingssuggest that cells may enter the apoptotic process from the G1 phase.
In detail for BALL1, treated versus control, 2 N cells: 38% versus
50% (P = .003); b2 N cells: 21% versus 5% (P = .008). For OP1,
treated versus control, 2 N cells: 41% versus 56% (P = .0007); b2 N
cells: 29% versus 12% (P = .005).
Pulse Exposure
Since CB-5083 reduced viability and induced apoptosis by 12 to
24 hours of treatment, we investigated the cytotoxic activity of
CB-5083 in BALL1, OP1, and REH cells after pulse exposure:
treatment of target cells for shorter durations (4 and 8 hours) but at
higher doses (1 μM and 2.5 μM) (Supplemental Figures 2 and 3).
After treatment with either vehicle or CB-5083 at the indicated doses
and intervals, cells were rigorously washed with PBS and seeded in
new media. Viability was evaluated at 72 hours with MTT assays.
Pulse exposure to CB-5083 (1 μM for 4 or 8 hours, or 2.5 μM for 4
hours) had little effect. In contrast, 2.5 μM drug pulse exposure for 8
hours significantly reduced viability at 72 hours. Moreover, 2.5 μM
drug pulse exposure for 8 hours significantly increased the rate of
apoptosis of BALL1 and OP1 cells at 24 hours.
Induction of ER Stress
As markers of ER stress, we investigated the activation of
IRE1-alpha and PERK pathways, and the synthesis of chaperones
of BALL1, OP1, and REH cells exposed to CB-5083 at different
concentrations and durations.
IRE1-alpha and XBP1 Splicing. Western blot showed
dose-dependent increased levels of IRE1-alpha in the BALL1 and
OP1 cells treated with CB-5083 (0.25, 0.5, and 0.75 μM; 24 hours)
(Figure 3C). Increase in IRE1-alpha in BALL1 appeared as early as 4
hours from exposure to CB-5083 (1 μM) (Supplemental Figure 4).
The activation of IRE1-alpha was confirmed by the demonstration of
the splicing of XBP1 into the short-form sXBP1 in the three cell lines
(BALL1, OP1, and REH) (Figure 5A). The XBP1 splicing was
strongly induced inBALL1: sXBP1 appeared early by 4 hours at 0.5μM
of drug and was maximum at 8 hours with higher CB-5083
concentrations (2.5 and 5 μM). XBP1 splicing occurred also in REH
cells, although with lower intensity, after exposure to higher doses of
drug (2.5 and 5 μM). OP1 showed an intermediate degree of XBP1
splicing between BALL1 and REH.
PERK and CHOP. For BALL 1 and OP1 cells treated with
CB-5083 (0.25, 0.5, and 0.75 μM; 24 hours), Western blot showed
increased levels of PERK compared to control, suggesting its
increased expression (Figure 3C). PERK plays an essential role in
the attenuation of mRNA translation (adaptive response). CHOP is
an activator of apoptosis following ER stress. Increased expression of
CHOP by CB-5083 was demonstrated at the protein level by
Western blot (Figure 3A). Levels of CHOP mRNA measured by
Q-PCR in BALL1, OP1, and REH after a short exposure (4 and 8
hours) of CB-5083 (0.5, 1, 2.5, 5 μM) showed that CHOP
expression significantly increased as early as 4 hours from exposure to
the drug at its lowest concentration for all the cell lines (Figure 5B).
CHOP expression increased proportionally with higher doses and
longer exposures, reaching the highest levels at 8-hour culture with 5 μM
of the drug: 67-, 34-, and 54-fold higher levels than the control in BALL1,
OP1, and REH cells, respectively.
Other genes (GADD34, DR5, ATF4, and caspase-2) potentially
involved in the death process triggered by an irresolvable ER stress
were also examined (Figure 5C). Treatment of BALL1 and OP1 with
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Figure 2. Apoptosis of BALL1 cells after treatment with CB-5083.Apoptosis was measured (Annexin V + propidium iodide positivity)
after treatment with CB-5083 (0.25, 0.5, and 0.75 μM) for 24, 48, and 72 hours. Lower panels: bar graph quantification of data (mean
[numbers in the boxes] ± SD of three experiments; ANOVA: all P b .0001; *: P b .05; ****: P b .0001).
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Figure 3. Protein expression of ER stress markers and PARP cleavage as determined by Western blot in BALL1 and OP1 cells after
treatment with CB-5083. Cells were treated with CB-5083 at a fixed dose (1 μM) for the indicated time (A), as well as for 24 hours at the
indicated CB-5083 concentrations (B and C). Western blots were probed with a series of antibodies directed against PERK, IRE1-alpha,
calnexin, GRP78, GRP94, PDI, CHOP, PARP, and cleaved caspase-3. β-Actin was used as a loading control.
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BALL1 OP1
Control
CB-5083
1 µM
12 h
Figure 4. Cell cycle analysis in BALL1 and OP1 cells after treatment with CB-5083. Cell cycle analysis of BALL1 and OP1 after treatment
with CB-5083 (1 μM, 12 hours). Staining was performed with propidium iodide. CTRL, diluent control. Quantification of data (mean ± SD
of three experiments) provided in bottom panels. **: P b .01.
756 Inhibition of p97 in B-ALL Gugliotta et al. Neoplasia Vol. 19, No. 10, 2017CB-5083 (5 μM; 8 hours) induced a significant increase of GADD34
mRNA expression (11.5- and 9.4-fold compared to control in BALL1
and OP1 cells, respectively), a downstream target of CHOP,
reinforcing the concept that this mechanism plays an important
role in inducing apoptosis in B-ALL cells. A slightly higher mRNA
expression compared to control was also found for DR5 (3.4- and
4.5-fold compared to control in BALL1 and OP1, respectively),
ATF4 (3.2- and 2.6-fold compared to control in BALL1 and OP1,
respectively), and caspase 2 (2.3- and 3.2-fold compared to control in
BALL1 and OP1, respectively).
Chaperones. For BALL 1 and OP1 cells treated with CB-5083
(0.25, 0.5, and 0.75 μM for 24 hours, as well as 1 μM for 4, 8, and 12
hours), Western blot demonstrated increased levels of GRP78,
GRP94, and PDI proteins, while no significant increase of calnexin,
another marker of ER stress, occurred (Figure 3, A and C). CB-5083
(5 μM, 8 hours) also increased expression of GRP78 mRNA (6.9-
and 9.1-fold) and GRP94 mRNA (7.4- and 5.6-fold) compared to
control in BALL1 and OP1 cells, respectively (Figure 5C). Moreover,CB-5083 (5 μM, 8 hours) significantly increased expression of two
other chaperones, DNAJC3 mRNA (8.7- and 7.5-fold) and DNAJB9
mRNA (9.3- and 13.7-fold), compared to control in BALL1 and
OP1 cells, respectively (Figure 5C).
Knockdown of XBP1, GRP78, and GRP94
Given the higher expression ofGRP78 andGRP94 and the increased
splicing of XBP1 after treatment with CB-5083, effect of the drug was
also examined when each of these genes was deleted.We usedmurine B
cells with floxed alleles (GRP78FL/FL; GRP94FL/FL; XBP1FL/FL)
transfected with the BCR-ABL oncogene (p190 for GRP78FL/FL and
GRP94FL/FL; P210 for XBP1FL/FL) as models of BCR-ABL+ B-ALL.
These BCR-ABL+ B-ALL floxed cells were transfected with either an
empty vector (EV) or estrogen-inducible CRE-recombinase, selected
with puromycin, and treated with 4-hydroxy-tamoxifen (4-OHT),
resulting in EV-GRP78+/+; EV-GRP94+/+; and EV-XBP1+/+ cells or in
CRE-GRP78−/−; CRE-GRP94−/−; and CRE-XBP1−/− cells (knock-
down cells).
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(1 μM) either alone (Supplemental Figure 5) or in combination with
CB-5083 (various concentrations) (Figure 6).
In CRE-GRP78 −/−, CRE-GRP94 −/−, and CRE-XBP1 −/−,
CB-5083 significantly reduced viability at 72 hours compared to
untreated cells, suggesting that the drug is effective even though these
cells lack these genes. Moreover, we compared the relative
(normalized to untreated cells) viability of CRE-XBP1 −/−,
CRE-GRP78 −/−, and CRE-GRP94 −/− versus EV-XBP1+/+,
EV-GRP78+/+, and EV-GRP94+/+ cells, respectively, during culture
with CB-5083. In the absence of XBP1 (CRE-XBP1−/−), the viability
after treatment with CB-5083 (0.3 – 0.4 – 0.5 μM) was significantly
lower compared to control (EV-XBP1+/+). In contrast, the viability
after treatment with CB-5083 was not significantly changed by the
absence of either GRP78 (CRE-GRP78 −/−) or GRP94
(CRE-GRP94−/−) compared to control cells (EV-GRP78+/+ and
EV-GRP94+/+, respectively) (Figure 6).
Combination Studies
The potential synergy of CB-5083 with other drugs was tested.
Firstly, the combination with drugs that represent the backbone of
B-ALL treatment, vincristine and prednisolone, was examined. The
combination of CB-5083 with vincristine for 24 hours was synergisticFigure 5. XBP1 splicing and expression of genes involved in ER stress a
(BALL1, OP1, REH) with either vehicle or CB-5083 at the indicated conc
XBP1 (sXBP1)were evaluatedwithRT-PCR (35 cycles) (A). CHOPexpressi
hourswithCB-5083 (5μM)versusdiluent control,mRNAwas isolatedand
in death pathways (C). GAPDH mRNA was used as loading control (A).
levels of GAPDH (B and C). Bar graphs represent mean (numbers in
comparisons tests ofCHOPexpressionareprovided inSupplemental Tab
were also evaluated in BALL1, OP1, and REH cells treated with the ER s(Figure 7), with combination indexes (CI) as low as 0.56 and 0.58 for
BALL1 and OP1 cells, respectively. Prior data showed that high
VCP/p97 expression correlated with poor prednisone response in
B-ALL [18]. We found that the combination of CB-5083 plus
prednisolone in two prednisolone-resistant cell lines (BALL1 and
REH) did not show synergistic activity (restoration of steroid
sensitivity) (Supplemental Figure 6). Other drugs inducing ER stress
were studied; neither the proteasome inhibitor bortezomib nor the
IRE1-alpha inhibitor HNA produced synergy with CB-5083
(Supplemental Figure 6).
Discussion
The present study showed that CB-5083, an orally available inhibitor
of the ATPase p97/VCP [15,16], has antileukemic activity through
the induction of ER stress using a wide panel of B-ALL cell lines,
including those harboring the fusion genes most frequently found in
adult and pediatric B-ALL [17]. We did not identify cell lines with
upfront resistance to the drug, with IC50s ranging from0.34 to 0.76μM.
Importantly, these concentrations are attainable in mice, without
significant toxicities [15]. Moreover, CB-5083 reduced the viability in
murine models of BCR-ABL+ (p190 and p210) B-ALL, with IC50s
comparable to those observed in human B-ALL cell lines. The
sensitivity to CB-5083 of B-ALL cells regardless of their underlyingfter treatment with CB-5083. After treatment of three B-ALL cell lines
entrations and intervals, mRNA was extracted, and XBP1 and spliced
onwasmeasuredbyQRT-PCR (B). InBALL1 andOP1cells treated for 8
used forQRT-PCR forgenes involved inunfoldedprotein responseand
Quantitative gene expression data were normalized to the expression
the boxes) ± SD of three experiments, each in triplicates. Multiple
les 2, 3 and4. Aspositive controls, XBP1splicing andCHOPexpression
tress inducer thapsigargin (Supplemental Figure 7).
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with high-risk genetic alterations (MLL rearrangements; BCR-ABL+).
Of note, the most sensitive B-ALL cell line (BALL1) harbors a
translocation involving c-myc. Myc-driven tumorigenesis is associated
with a high level of protein synthesis [19] and high levels of ER stress
that trigger an adaptive UPR, required for cell survival and proliferation
[20]. This finding reinforces the theory that CB-5083 might be
particularly effective in cells heavily dependent on UPR for survival, as
was demonstrated in multiple myeloma [15]. Moreover, this concept
suggests that CB-5083 will be potent against tumors harboring myc
translocations (e.g., Burkitt's lymphoma).
The proliferation assays highlighted that CB-5083, depending on the
exposure and concentration, has both cytostatic and cytotoxic activity.
The cytotoxicity was demonstrated by the induction of apoptosis, which
increased with higher concentrations or longer exposures to the drug.
Moreover, short exposure to high concentrations of the drug (pulse
exposure), similar to peak concentrations reached in vivo, is enough to
reduce the cell viability and to induce apoptosis.
The cell cycle analysis showed that CB-5083 significantly reduced
the proportion of 2 N cells (G1 phase) and increased b2 N cells(sub-G1; apoptotic) without affecting the proportion of N2 N cells
(S phase) and 4 N cells (G2/M phase). The data suggest that these
treated cells might enter into apoptosis during their G1 phase. These
findings are consistent with the notion that B-ALL cells might be
particularly susceptible to ER stress in G1 when, physiologically, a
high burden of protein synthesis occurs and, consequently, a higher
demand for efficient management of unfolded proteins.
The clonogenic experiments using OP1 and NALM6 cells
confirmed the activity of CB-5083, with a significant reduction in
the number of colonies after a continuous exposure to the drug.
However, the antiproliferative effects were lower than expected because
we still observed moderate clonogenic growth after treatment with 1 μM
CB-5083 (38% in OP1 and 56% in NALM6 compared to dishes
containing diluent control). The cause could be multifactorial including
that the half-life of the drug in methyl-cellulose is short. In this context,
the sigmoidal shape and the steep slope of the concentration/viability
curves observed for the cell lines suggest that small variations in CB-5083
concentration may cause dramatic changes in the potency of the drug.
Previously, ER stress and UPR were identified as therapeutic
targets in B-ALL [6]. Here, we show that CB-5083 has a significant
Figure 5. (continued.)
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severe ER stress. Indeed, the ER stress was documented through: 1)
prominent expression of the chaperones (GRP78, GRP94, PDI,
DNAJC3, and DNAJB9); 2) increased activation of IRE1-alpha, as
demonstrated by prominent splicing of XBP1; and 3) activation of
PERK resulting in significant overexpression of CHOP and its
downstream genes (particularly GADD34 and DR5).
We showed that the knockdown of either of the chaperones
GRP78 or GRP94 did not modify the sensitivity of B-ALL cells to
CB-5083. This suggests that their overexpression following CB-5083
treatment is simply a marker of ER stress induction and that GRP78
and GRP94 do not have a major role in mediating CB-5083
cytotoxicity in B-ALL cells. This is congruent with the finding that
silencing of GRP78 (shRNA) did not significantly affect the
sensitivity to CB-5083 against colon cancer cell lines [15].
In contrast, we showed that the absence of XBP1 increased the
sensitivity to CB-5083, suggesting that the XBP1 splicing counteracts
the activity of CB-5083, probably mitigating the ER stress. Moreover,
it was previously noted that deletion of XBP1 is associated with a
compensatory IRE1-alpha hyperphosphorylation [21,22], possibly
leading to increased and sustained RIDD (regulated IRE1-dependent
decay) that promotes apoptosis [23,24]. Therefore, we may
hypothesize that modulation of RIDD is relevant in mediating
CB-5083 cytotoxicity. This could explain why CB-5083 and theIRE1-alpha inhibitor HNA were not synergistic under severe ER
stress induced by CB-5083. Inhibition of RIDD could have
detrimental effects (decreased proapoptotic signaling) that overcome
the benefits (increased ER stress) of XBP1 splicing inhibition.
Finally, vincristine was synergistic with CB-5083 with combina-
tion indexes [25] as low as 0.56 and 0.58 for BALL1 and OP1 cells,
respectively. Vincristine mainly acts by blocking cell division. Perhaps
vincristine kills cells that, despite their inhibition of p97, are able to
progress from G1 to the S and G2/M phase. In contrast, even though
high p97-VCP expression is correlated with a poor prednisone
response in B-ALL [18], the inhibition of p97 with CB-5083 did not
restore prednisolone sensitivity in prednisolone-resistant cell lines
(BALL1 and REH), and the combination was not synergistic.
Moreover, bortezomib, a proteasome inhibitor that causes ER stress,
was not synergistic with CB-5083.
Conclusions
CB-5083, an orally bioavailable p97 inhibitor, has significant activity
against a diverse panel of B-ALL cell lines, regardless of their genetic
alterations. The drug causes a severe ER stress, inducing apoptosis
mainly through the PERK-CHOP axis. A potentially useful synergy
with vincristine, a backbone of ALL therapy, was discovered.
Targeting of VCP/p97 is a novel promising therapeutic approach in
B-ALL with high-risk features.
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Figure 6. CB-5083 activity in GRP78, GRP94, and XBP1 knockdown models of BCR-ABL+ ALL.BCR-ABL+ B-ALL cells with floxed alleles
(either GRP78FL/FL, GRP94FL/FL, or XBP1FL/FL), transfected with either empty vector (EV) or CRE recombinase, inducible with
4-hydroxy-tamoxifen (4-OHT), treated for 72 hours with 4-OHT 1 μM and CB-5083 at different concentrations; viability was measured by
MTT assays. Bar graphs represent mean ± SD of three experiments, each in triplicates. *: P b .05; **: P b .01.
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Figure 7. Synergistic activity of CB-5083 and vincristine. BALL1 and OP1 cells were treated for 24 hours with a combination of different
concentrations of CB-5083 (0.25, 0.5, and 0.75 μM) and vincristine (2 and 4 nM). Viability was measured by MTT (n = 3; each in
triplicates). Fractional inhibition (Fa) is defined as the reduction of viability in treated cells compared to controls (Fa = 0, no inhibition;
Fa = 1, complete inhibition). Combination index (CI) b 1 represents synergistic activity; = 1, additive effect. Right panels: CI and Fa for
each combination tested.
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